



[Date]

[Name], [Degree]
[Institution]
[Street Address]
[City, State Zip]

Dear Dr. [Name],

I'm writing to inform you that the [REDACTED] Trial, a clinical research trial of an investigational vaccine for cytomegalovirus (CMV), is currently enrolling healthy individuals between the ages of 18–40 who are of Japanese descent and are living in the United States.

I invite you to pass along the enclosed brochures to those you feel may be interested in participating.

The vaccine being tested in this trial is called [REDACTED]. The investigational vaccine is not made from a weakened or inactive virus. Instead, it includes a short segment of messenger ribonucleic acid (mRNA) that encodes for two proteins residing on the surface of the CMV virus. The vaccine is not gene therapy, and does not cross the nucleus of a cell to integrate with the host genome. This is a phase 1 trial, meaning the investigational vaccine is being evaluated in healthy participants, specifically in participants of Japanese descent to explore any potential differences in safety and immune response.

The total duration of participation will last approximately 12 months and includes 9 phone calls and up to 11 visits to the trial site. Participants will receive 3 injections of investigational vaccine over a 6-month period. Following their last vaccination, participants are followed for safety for a minimum of 6 months.

Eligible participants must:

- Be of Japanese descent, 18–40 years of age.
- Not have received or have plans to receive any non-trial vaccine within 28 days prior to or after the trial vaccination. In addition, the following apply:
 - Any COVID-19 vaccination series (regardless of manufacturer) must have been completed a minimum of 28 days prior to or after receiving any dose of the trial injections.
 - Influenza vaccines may be given more than 14 days prior to or after the trial injections.

Additional eligibility criteria apply. If you have any questions about this trial and would like to discuss it further or obtain additional information, please contact my office at [PI Phone].

Your assistance in referring individuals is vital to helping us advance the development of vaccines for the prevention of CMV infection. Thank you.

Sincerely,

[PI Name], [Degree]
Enc.

